Cargando…

The BILAG-2004 index is sensitive to change for assessment of SLE disease activity

Objective. To determine if the BILAG-2004 index is sensitive to change for assessment of SLE disease activity. Methods. This was a prospective multi-centre longitudinal study of SLE patients. At every assessment, data were collected on disease activity (BILAG-2004 index) and treatment. Analyses were...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yee, Chee-Seng, Farewell, Vernon, Isenberg, David A., Griffiths, Bridget, Teh, Lee-Suan, Bruce, Ian N., Ahmad, Yasmeen, Rahman, Anisur, Prabu, Athiveeraramapandian, Akil, Mohammed, McHugh, Neil, Edwards, Christopher, D’Cruz, David, Khamashta, Munther A., Maddison, Peter, Gordon, Caroline
Formato:	Texto
Lenguaje:	English
Publicado:	Oxford University Press 2009
Materias:	Clinical
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2681285/ https://www.ncbi.nlm.nih.gov/pubmed/19395542 http://dx.doi.org/10.1093/rheumatology/kep064

Ejemplares similares

The BILAG-2004 systems tally—a novel way of representing the BILAG-2004 index scores longitudinally
por: Yee, Chee-Seng, et al.
Publicado: (2012)

Numerical scoring for the BILAG-2004 index
por: Yee, Chee-Seng, et al.
Publicado: (2010)

Numerical scoring for the Classic BILAG index
por: Cresswell, Lynne, et al.
Publicado: (2009)

The BILAG2004-Pregnancy index is reliable for assessment of disease activity in pregnant SLE patients
por: Yee, Chee-Seng, et al.
Publicado: (2012)

British isles lupus assessment group 2004 index is valid for assessment of disease activity in systemic lupus erythematosus
por: Yee, Chee-Seng, et al.
Publicado: (2007)

The BILAG2004-Pregnancy Index is a valid disease activity outcome measure for pregnant SLE patients
por: Yee, Chee-Seng, et al.
Publicado: (2022)

The use of Systemic Lupus Erythematosus Disease Activity Index-2000 to define active disease and minimal clinically meaningful change based on data from a large cohort of systemic lupus erythematosus patients
por: Yee, Chee-Seng, et al.
Publicado: (2011)

Easy-BILAG: a new tool for simplified recording of SLE disease activity using BILAG-2004 index
por: Carter, Lucy M, et al.
Publicado: (2022)

Predictors of BILAG-based outcomes in patients with SLE: Analysis from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort
por: David, Trixy, et al.
Publicado: (2023)

Short-term efficacy and safety of rituximab therapy in refractory systemic lupus erythematosus: results from the British Isles Lupus Assessment Group Biologics Register
por: McCarthy, Eoghan M, et al.
Publicado: (2018)

Outcomes of children born to mothers with systemic lupus erythematosus exposed to hydroxychloroquine or azathioprine
por: Reynolds, John A, et al.
Publicado: (2022)

Sensitivity to Change and Minimal Important Differences of the LupusQoL in Patients With Systemic Lupus Erythematosus
por: McElhone, Kathleen, et al.
Publicado: (2016)

Flares in patients with systemic lupus erythematosus
por: McElhone, Kathleen, et al.
Publicado: (2020)

How can we accurately measure disease activity during pregnancy in systemic lupus erythematosus? New insights from the BILAG-2004 Pregnancy Index
por: Ali, Sasha, et al.
Publicado: (2023)

Correction to: How can we accurately measure disease activity during pregnancy in systemic lupus erythematosus? New insights from the BILAG-2004 Pregnancy Index
Publicado: (2023)

Direct Oral Anticoagulants Use in Antiphospholipid Syndrome: Are These Drugs an Effective and Safe Alternative to Warfarin? A Systematic Review of the Literature: Comment
por: Cohen, Hannah, et al.
Publicado: (2017)

Rivaroxaban in antiphospholipid syndrome (RAPS) protocol: a prospective, randomized controlled phase II/III clinical trial of rivaroxaban versus warfarin in patients with thrombotic antiphospholipid syndrome, with or without SLE
por: Cohen, H, et al.
Publicado: (2015)

Targeted Therapy for SLE—What Works, What Doesn’t, What’s Next
por: Venturelli, Veronica, et al.
Publicado: (2023)

Antibodies to domain I of β-2-glycoprotein I and IgA antiphospholipid antibodies in patients with ‘seronegative’ antiphospholipid syndrome
por: Cousins, Laura, et al.
Publicado: (2015)

PReS13-SPK-1129: Biologic therapies in SLE
por: Isenberg, DA
Publicado: (2013)

The immunological personality of close relatives of SLE patients
por: Salaman, M R, et al.
Publicado: (2017)

Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial)
por: Isenberg, David, et al.
Publicado: (2015)

Bruton’s Tyrosine Kinase Inhibitors: A New Therapeutic Target for the Treatment of SLE?
por: Lorenzo-Vizcaya, Ana, et al.
Publicado: (2020)

B-cell depletion in SLE: clinical and trial experience with rituximab and ocrelizumab and implications for study design
por: Reddy, Venkat, et al.
Publicado: (2013)

Long-term anifrolumab safe in SLE
por: McHugh, Jessica
Publicado: (2023)

Ultrasound to identify systemic lupus erythematosus patients with musculoskeletal symptoms who respond best to therapy: the US Evaluation For mUsculoskeletal Lupus longitudinal multicentre study
por: Mahmoud, Khaled, et al.
Publicado: (2021)

The Antiphospholipid Syndrome
por: Hughes, Graham R V, et al.
Publicado: (1994)

Can we predict if patients with SLE will require more than one cycle of rituximab?
por: Fernández González, Raquel, et al.
Publicado: (2021)

Effects of atacicept on disease activity in patients with moderate to severe systemic lupus erythematosus: APRIL-SLE randomized trial
por: Isenberg, David, et al.
Publicado: (2014)

Improved monitoring of clinical response in Systemic Lupus Erythematosus by longitudinal trend in soluble vascular cell adhesion molecule-1
por: Lewis, Myles J., et al.
Publicado: (2016)

Safety and efficacy of belimumab in older adults with SLE: results of an integrated analysis of clinical trial data
por: D'Cruz, David, et al.
Publicado: (2023)

Differences in disease phenotype and severity in SLE across age groups
por: Ambrose, N, et al.
Publicado: (2016)

Psychosis in systemic lupus erythematosus (SLE): 40-year experience of a specialist centre
por: Abrol, Esha, et al.
Publicado: (2021)

Progression of subclinical and clinical cardiovascular disease in a UK SLE cohort: the role of classic and SLE-related factors
por: Haque, Sahena, et al.
Publicado: (2018)

Low aspirin use and high prevalence of pre-eclampsia risk factors among pregnant women in a multinational SLE inception cohort
por: Mendel, Arielle, et al.
Publicado: (2019)

Heart failure in a woman with SLE, anti-phospholipid syndrome and Fabry’s disease
por: Nandagudi, A, et al.
Publicado: (2013)

Lupus clinical trial eligibility in a real-world setting: results from the British Isles Lupus Assessment Group-Biologics Register (BILAG-BR)
por: Dyball, Sarah, et al.
Publicado: (2021)

The role of cardiac magnetic resonance imaging in the assessment of systemic lupus erythematosis (SLE)
por: Norman, Wendy, et al.
Publicado: (2009)

Post Hoc Analysis of the Phase II/III APRIL‐SLE Study: Association Between Response to Atacicept and Serum Biomarkers Including BLyS and APRIL
por: Gordon, Caroline, et al.
Publicado: (2016)

Pathogenic autoantibodies from patients with lupus nephritis cause reduced tyrosine phosphorylation of podocyte proteins, including tubulin
por: Manson, Jessica J, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_hoi3ooo5m0g5bss1kjjdqnb8gf